胆汁淤积性肝损伤中MAFG失调机制及肝癌发生发展研究
本研究探讨胆汁淤积性肝损伤中MAFG上调机制及SAMe、UDCA的干预作用,并分析OCA对MAFG表达和肿瘤生长的影响;发现MAFG在胆汁淤积组织及人胆管癌、肝细胞癌中表达升高,高MAFG与乙肝、血管侵犯和较短生存期相关;SAMe和UDCA通过共同及不同机制降低LCA诱导的MAFG表达,而OCA增加MAFG表达并促进肿瘤生长。
要点
- MAFG在胆汁淤积肝组织及人胆管癌、肝细胞癌中表达升高,高MAFG与乙肝、血管侵犯和较短生存期相关。
- SAMe和UDCA通过共同及不同机制降低LCA诱导的MAFG表达。
- OCA增加MAFG、MAT2A、c-MYC表达并促进人肝癌和胆管癌细胞增殖及裸鼠异种移植瘤生长。
核心结论
- MAFG在胆汁淤积细胞和组织以及人胆管癌和肝细胞癌标本中表达升高,高表达与肿瘤进展和较短生存期相关。
- SAMe和UDCA通过共同及不同机制降低胆汁淤积诱导的MAFG表达。
- OCA诱导MAFG表达、癌细胞增殖及小鼠异种移植瘤生长。
研究设计与样本
- 研究纳入美国加利福尼亚州手术切除的7例人胆管癌标本及癌旁非肿瘤组织,以及中国113例肝细胞癌标本及癌旁非肿瘤组织,并分析患者临床资料。
- 采用免疫组化分析组织,在MzChA-1、KMCH、Hep3B和HepG2细胞中过表达或用小干扰RNA敲低MAT1A、MAT2A、c-MYC和MAFG,部分细胞与石胆酸、SAMe、UDCA(100 μM)或法尼醇X受体激动剂共孵育。
- 采用实时聚合酶链反应、免疫印迹和瞬时转染检测MAFG表达和启动子活性,用电泳迁移率变动分析和染色质免疫沉淀研究启动子区域结合蛋白。
- 研究小鼠模型包括胆管结扎、原位胆管癌、胆汁淤积诱导的胆管癌、二乙基亚硝胺诱导的肝肿瘤和异种移植瘤。
主要发现
- 石胆酸激活HepG2和MzChA-1细胞中MAFG表达,需要MAFG启动子中的激活蛋白-1、核因子-κB和E-box位点。
- 石胆酸降低细胞中MAT1A表达但增加MAT2A表达;过表达MAT2A增加MAFG启动子活性,而敲低MAT2A降低其活性。
- MAT1A和MAT2A对激活蛋白-1、核因子-κB和E-box介导的启动子活性有相反作用。
- 二乙基亚硝胺诱导的小鼠肝肿瘤中MAFG和MAT2A表达增加,MAT1A表达降低。
- OCA增加MAFG、MAT2A和c-MYC表达但降低MAT1A表达;OCA促进人肝癌和胆管癌细胞系增殖,OCA处理裸鼠的异种移植瘤大于赋形剂处理小鼠。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: MAF bZIP transcription factor G (MAFG) is activated by the farnesoid X receptor to repress bile acid synthesis. However, expression of MAFG increases during cholestatic liver injury in mice and in cholangiocarcinomas. MAFG interacts directly with methionine adenosyltransferase α1 (MATα1) and other transcription factors at the E-box element to repress transcription. We studied mechanisms of MAFG up-regulation in cholestatic tissues and the pathways by which S-adenosylmethionine (SAMe) and ursodeoxycholic acid (UDCA) prevent the increase in MAFG expression. We also investigated whether obeticholic acid (OCA), an farnesoid X receptor agonist, affects MAFG expression and how it contributes to tumor growth in mice. METHODS: We obtained 7 human cholangiocarcinoma specimens and adjacent non-tumor tissues from patients that underwent surgical resection in California and 113 hepatocellular carcinoma (HCC) specimens and adjacent non-tumor tissues from China, along with clinical data from patients. Tissues were analyzed by immunohistochemistry. MAT1A, MAT2A, c-MYC, and MAFG were overexpressed or knocked down with small interfering RNAs in MzChA-1, KMCH, Hep3B, and HepG2 cells; some cells were incubated with lithocholic acid (LCA, which causes the same changes in gene expression observed during chronic cholestatic liver injury in mice), SAMe, UDCA (100 μM), or farnesoid X receptor agonists. MAFG expression and promoter activity were measured using real-time polymerase chain reaction, immunoblot, and transient transfection. We performed electrophoretic mobility shift, and chromatin immunoprecipitation assays to study proteins that occupy promoter regions. We studied mice with bile-duct ligation, orthotopic cholangiocarcinomas, cholestasis-induced cholangiocarcinoma, diethylnitrosamine-induced liver tumors, and xenograft tumors. RESULTS: LCA activated expression of MAFG in HepG2 and MzChA-1 cells, which required the activator protein-1, nuclear factor-κB, and E-box sites in the MAFG promoter. LCA reduced expression of MAT1A but increased expression of MAT2A in cells. Overexpression of MAT2A increased activity of the MAFG promoter, whereas knockdown of MAT2A reduced it. MAT1A and MAT2A had opposite effects on the activator protein-1, nuclear factor-κB, and E-box-mediated promoter activity. Expression of MAFG and MAT2A increased, and expression of MAT1A decreased, in diethylnitrosamine-induced liver tumors in mice. SAMe and UDCA had shared and distinct mechanisms of preventing LCA-mediated increased expression of MAFG. OCA increased expression of MAFG, MAT2A, and c-MYC, but reduced expression of MAT1A. Incubation of human liver and biliary cancer cells lines with OCA promoted their proliferation; in nude mice given OCA, xenograft tumors were larger than in mice given vehicle. Levels of MAFG were increased in human HCC and cholangiocarcinoma tissues compared with non-tumor tissues. High levels of MAFG in HCC samples correlated with hepatitis B, vascular invasion, and shorter survival times of patients. CONCLUSIONS: Expression of MAFG increases in cells and tissues with cholestasis, as well as in human cholangiocarcinoma and HCC specimens; high expression levels correlate with tumor progression and reduced survival time. SAMe and UDCA reduce expression of MAFG in response to cholestasis, by shared and distinct mechanisms. OCA induces MAFG expression, cancer cell proliferation, and growth of xenograft tumors in mice.
引用
- Liu T, Yang H, Fan W, et al. Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer. Gastroenterology. 2018. PMID: 29733835. doi:10.1053/j.gastro.2018.04.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。